GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2009

Eden Biodesign to Manufacture Wound Healing Compound for Omnio

  • Swedish company Omnio Healer selected Eden Biodesign to carry out process development and cGMP mammalian cell manufacture of its lead recombinant protein candidate, which is in development for the treatment of chronic eardrum wounds. The candidate is currently in late preclinical development and is expected to enter the clinic during late 2010.

    One of Karolinska Development’s portfolio companies, Omnio Healer was established in 2006 to exploit the proinflammatory properties of the anticoagulation system for applications in wound healing and anti-infectives.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?